Actively Recruiting
Non-invasive Goal-directed thErapy oN cIrcUlatory Shock
Led by University of Sao Paulo · Updated on 2024-08-26
380
Participants Needed
1
Research Sites
140 weeks
Total Duration
On this page
Sponsors
U
University of Sao Paulo
Lead Sponsor
I
Instituto Dante Pazzanese de Cardiologia
Collaborating Sponsor
AI-Summary
What this Trial Is About
Circulatory shock occurs when the oxygen supply to the tissues decreases, leading to cellular damage and affecting about one-third of patients admitted to Intensive Care Units (ICUs). Cardiac Output (CO) is defined as the volume of blood ejected by the left ventricle per minute and is a crucial hemodynamic parameter for monitoring patients with signs of circulatory shock. However, this parameter is underutilized in patients treated in Emergency Units because its measurement typically involves invasive methods, which are not commonly available in this setting. Any method capable of measuring CO without the need for pulmonary artery catheter insertion is referred to as minimally invasive CO monitoring. Evaluating these parameters allows for a quicker determination of the etiology of circulatory shock, enabling the early initiation of goal-directed therapy. Goal-directed therapy has been proven effective in reducing morbidity and mortality, ICU length of stay, and mechanical ventilation duration in ICU patients who respond to fluid resuscitation. Currently, there are no data on the impact of a hemodynamic optimization strategy in patients during the early hours of shock. The objective is to assess whether goal-directed hemodynamic therapy, through non-invasive hemodynamic monitoring, reduces the time required for hemodynamic resuscitation in patients with septic shock. A multicenter, randomized, open-label study will be conducted in Emergency Units, Intensive Care Units, and Hospital Wards. Patients over 18 years old admitted with signs of septic shock (defined as systolic blood pressure less than 90 mmHg and/or mean arterial pressure less than 65 mmHg, along with at least one of the following criteria: lactate greater than 2 mEq/L, oliguria, neurological alteration, or capillary refill time greater than 3 seconds) will be included Participants will be randomized in a 1:1 ratio into two groups. In the Goal-Directed Therapy Group, patients will be monitored using the HemoSphere HPI™ (Edwards Life Sciences, Irvine, CA, USA), where parameters such as cardiac index (CI), stroke volume (SV), systolic blood pressure (SBP), mean arterial pressure (MAP), and HPI will guide medical management. In the Conventional Therapy Group, patients will be evaluated with the standard hemodynamic monitoring equipment typically found in emergency units..
CONDITIONS
Official Title
Non-invasive Goal-directed thErapy oN cIrcUlatory Shock
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age greater than 18 years
- Patients admitted to Emergency Units, Intensive Care Units, and Wards within 3 hours of septic shock diagnosis
- Systolic Blood Pressure less than 90 mmHg and/or Mean Arterial Pressure less than 65 mmHg (with or without norepinephrine less than 0.5 mcg/kg/min)
- Clinical signs of infection and at least one of the following: lactate greater than 2 mEq/L, oliguria (urine output less than 0.5 mL/kg/h for at least 6 hours), neurological changes (mental confusion, decreased consciousness, agitation, disorientation), capillary refill time greater than 3 seconds, or poor skin perfusion
- Signed Informed Consent Form
You will not qualify if you...
- Hospital admission time greater than 24 hours
- Significant edema in the fingers
- Severe peripheral vasoconstriction
- Use of norepinephrine at a dose greater than or equal to 0.5 mcg/kg/min
- Presence of significant aortic insufficiency
- Patients undergoing renal replacement therapy
- Patients with ST-segment elevation myocardial infarction
- Patients requiring invasive mechanical ventilation
- Patients already participating in another study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Instituto do Coração
São Paulo, Brazil, 05403-000
Actively Recruiting
Research Team
L
Ludhmila A Hajjar, MD, PhD
CONTACT
A
ARO F InCor, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here